Erythropoietin dosing regimen for treating anemia

• US 20030134795A1
• Filed: 11/26/2002
• Published: 07/17/2003
• Est. Priority Date: 11/28/2001
• Status: Active Grant

• Current Assignee: Ortho-McNeil Pharmaceutical Incorporated (Johnson & Johnson)
• Original Assignee: Ortho-McNeil Pharmaceutical Incorporated (Johnson & Johnson)
• Inventors: Farrell, Francis
• Granted Patent: US 7,232,797 B2
• Time in Patent Office: Days
• US Class Current: 514/12
• CPC Class Codes: A61K 38/1816 Erythropoietin [EPO]
• CPC Class Codes: A61P 7/06 Antianaemics

Abstract

The present invention provides a new subcutaneous injection dosing regimen for erythropoietin to treat anemia. The new erythropoietin treatment regimen of the present invention results in improved hemoglobin levels with less frequent dosing.

Claims

1. A regimen for erythropoietin treatment comprising:

a) dosing a patient by subcutaneous injection once every week with a therapeutically effective amount of erythropoietin until a hemoglobin increase of about 2 g/dL is achieved; and

b) dosing said patient by subcutaneous injection once every two weeks with an amount of erythropoietin that is greater than the amount dosed in step (a).

2. A regimen for erythropoietin treatment comprising:

a) dosing a patient by subcutaneous injection once every week with a therapeutically effective amount of erythropoietin until a hemoglobin increase of about 2 g/dL is achieved; and

b) dosing said patient by subcutaneous injection once every three weeks with an amount of erythropoietin that is greater than the amount dosed in step (a).